Sirtex Medical’s DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC
The DOORwaY90 study met its prespecified co-primary endpoints, achieving a best overall response rate (ORR) of 99% WOBURN, Mass., April 13, 2026 /PRNewswire/ — Sirtex Medical (“Sirtex”), a leading manufacturer of interventional oncology
